A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab versus investigator's choice in the treatment of patients with relapsed/Refractory adult tTcell leukemia-lymphoma: overall response rate, progression-free survival, and overall survival

OA Location

https://doi.org/10.1182/blood.V128.22.4159.4159

Author(s)

Phillips, Adrienne

Fields, Paul

Hermine, Olivier

Ramos, Juan Carlos

Beltran, Brady E

more

Type

Conference Paper

Date Issued

2016-12-02

Date Acceptance

2021-06-01

Citation

Blood, 2016, 128 (22), pp.4159-4159

URI

http://hdl.handle.net/10044/1/104890

URL

https://www.sciencedirect.com/science/article/pii/S0006497119341606

DOI

https://www.dx.doi.org/10.1182/blood.V128.22.4159.4159

ISSN

0006-4971

Publisher

American Society of Hematology

Start Page

4159

End Page

4159

Journal / Book Title

Blood

Volume

128

Issue

22

Copyright Statement

© 2016 by The American Society of Hematology

Identifier

https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000394452308057&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Source

58th ASH Annual Meeting and Exposition

Subjects

Hematology

Life Sciences & Biomedicine

Science & Technology

Publication Status

Published

Start Date

2016-12-03

Finish Date

2016-12-06

Coverage Spatial

San Diego, CA

Date Publish Online

2021-06-15